CAGRISEMA
Tried CAGRISEMA? Be part of the collective knowledge. Share your experience - your insights help others on their journey.
What Is CAGRISEMA?
CagriSema is a fixed-dose combination injectable peptide consisting of semaglutide 2.4 mg (a GLP-1 receptor agonist) and cagrilintide 2.4 mg (a long-acting amylin analogue), developed by Novo Nordisk. It targets dual satiety pathways — amylin for gastric emptying and satiety, GLP-1 for appetite suppression and insulin secretion — to achieve greater weight loss than either component alone. Primarily under development for obesity and type 2 diabetes.
CAGRISEMA Research & Studies
01 Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity ▸
REDEFINE 1 phase 3a trial in 3,417 adults showed CagriSema achieved 22.7% mean weight loss at 68 weeks, superior to semaglutide alone (14.9%) and cagrilintide alone (11.5%). 60% of participants lost at least 20% of body weight.
View Study (NEJM)02 Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes ▸
REDEFINE 2 trial in 1,206 adults with T2D across 12 countries. CagriSema achieved 15.7% weight loss and 73.5% of patients reached HbA1c of 6.5% or lower vs 15.9% on placebo.
View Study (PubMed)03 Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a phase 2 trial ▸
32-week trial in 92 participants with T2D. CagriSema achieved 15.6% weight loss vs 5.1% with semaglutide alone and 8.1% with cagrilintide alone. HbA1c reduction was 2.2 percentage points.
View Study (The Lancet)04 Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide as Anti-Obesity Medications: A Systematic Review and Meta-Analysis ▸
Meta-analysis of 3 RCTs confirmed CagriSema achieves significantly greater weight loss than semaglutide 2.4 mg alone. GI adverse events were higher but serious adverse events were comparable between groups.
View Study (PubMed)CAGRISEMA User Reviews & Experiences
*Based on large scale analysis of publicly available user experiences
Strong initial excitement after REDEFINE 1/2 results showing superior weight loss over semaglutide alone, but sentiment cooled after the February 2026 REDEFINE 4 trial failed to demonstrate noninferiority against tirzepatide (Zepbound). Still demonstrates clinically meaningful 23% weight loss and remains on track for potential FDA approval.
CAGRISEMA Benefits, Dosage & Side Effects
- Dual Pathway Action: Combines amylin-mediated satiety and gastric emptying with GLP-1 appetite suppression and insulin secretion for additive weight loss.
- Significant Weight Reduction: 20-23% body weight loss over 68-84 weeks in non-diabetic adults with obesity.
- Glycemic Control: Lowers HbA1c by 1.5-2.2 percentage points in people with type 2 diabetes.
- Cardiovascular Markers: Reduces systolic blood pressure by ~10.9 mmHg and lowers C-reactive protein (inflammation marker) by 68.9%.
- Prediabetes Reversal: 88% of participants with prediabetes returned to normoglycemia in trials.
- Superior to Components: REDEFINE 1 showed 22.7% weight loss vs 14.9% for semaglutide alone and 11.5% for cagrilintide alone.
- Strong Responder Rate: 60% of participants achieved at least 20% weight loss; 40.4% achieved at least 25%.
- T2D Efficacy: 15.7% weight loss in diabetic population (REDEFINE 2), with 73.5% achieving target HbA1c.
- Inferior to Tirzepatide: REDEFINE 4 showed CagriSema at 23.0% vs tirzepatide 25.5% weight loss — did not meet noninferiority endpoint.
- Maintenance Dose: Cagrilintide 2.4 mg + semaglutide 2.4 mg, once weekly subcutaneous injection.
- Titration Schedule: Starts at 0.25 mg/week, escalating through 0.5 mg, 1.0 mg, 1.7 mg over 16 weeks to reach maintenance 2.4 mg at week 17.
- Weekly Administration: Both components have long half-lives (~158-184 hours), enabling once-weekly dosing.
- Higher-Dose Version: Novo Nordisk plans trials of CagriSema 2.4/7.2 mg (higher semaglutide dose) starting H2 2026.
- GI Events: 79.6% of CagriSema users experienced gastrointestinal adverse events vs 39.9% on placebo.
- Nausea: Most common side effect at 55%, usually mild-to-moderate and diminishing during titration.
- Constipation and Vomiting: Reported in 30.7% and 26.1% of users respectively.
- Generally Transient: Most GI side effects decrease over time as the body adjusts during dose escalation.
- Low Discontinuation: Only 5.9% discontinued due to adverse events in REDEFINE 1.
- Not Yet FDA-Approved: NDA submitted to FDA in December 2025, decision expected late 2026 or early 2027.
- No Market Availability: Not approved in any country as of February 2026.
- First-in-Class: Would be the first FDA-approved combination of a GLP-1 agonist and amylin analogue if approved.
- Research Chemical: May be available from some peptide suppliers, but no commercial product exists.
Related Compounds
Community Reviews
Share your experience with CAGRISEMA and help others make informed decisions.
Write a Review
Sign in to leave a review